10-K: Avanos Medical Reports Significant Goodwill and Intangible Asset Impairments in 2024 Annual Results

Avanos Medical's 2024 Form 10-K reveals substantial goodwill and intangible asset impairments, impacting operating results despite a slight increase in net sales.

Summary

• Avanos Medical, Inc.'s Form 10-K for the year ended December 31, 2024, highlights a year marked by significant financial adjustments and strategic shifts.
• The company reported a net loss of $392.1 million, primarily due to a $336.5 million goodwill impairment and a $100.2 million intangible asset impairment.
• Net sales increased by 2.2% to $687.8 million, driven by growth in Digestive Health and Interventional Pain portfolios, but offset by unfavorable pricing in HA products.
• The company continued its three-year transformation process, focusing on Digestive Health and Pain Management and Recovery product categories.
• Avanos completed the sale of its Respiratory Health (RH) business for $110.0 million in cash on October 2, 2023.
• The company incurred restructuring expenses related to the transformation process and the RH divestiture.
• Avanos acquired Diros Technology Inc. in July 2023 for approximately $53.0 million, expanding its radiofrequency ablation (RFA) product offerings.
• The company's financial position reflects a decrease in total assets from $1.69 billion in 2023 to $1.15 billion in 2024, largely due to the goodwill impairment.
• Avanos continues to manage its capital resources, including a share repurchase program, and remains in compliance with its debt covenants.

Sentiment

Score: 3

Explanation: The document presents a mixed picture, with increased sales offset by significant losses due to impairments. The ongoing restructuring and divestiture suggest strategic adjustments, but the overall tone is negative due to the financial losses.

Positives

• Net sales increased by 2.2% to $687.8 million, indicating growth in core business areas.
• The company completed the divestiture of the Respiratory Health business, streamlining its portfolio.
• The acquisition of Diros Technology Inc. expands Avanos's offerings in the interventional pain market.
• Selling and general expenses decreased, reflecting cost management efforts.
• The company remains in compliance with its debt covenants.

Negatives

• Avanos Medical reported a significant net loss of $392.1 million for 2024.
• The company recognized substantial goodwill and intangible asset impairments totaling $436.7 million.
• Gross profit margin decreased from 56.4% in 2023 to 55.4% in 2024.
• Operating loss was $396.2 million compared to an operating profit of $4.2 million in the prior year.

Risks

• The company faces strong competition in the medical device industry.
• Failure to successfully develop, acquire, or market competitive products could adversely affect the business.
• Supply chain disruptions and inflationary pressures could impact manufacturing costs and profitability.
• Healthcare reform and legislative changes could affect customer purchasing decisions.
• Extensive government regulation requires significant expenses to ensure compliance.
• Product liability claims and litigation could be costly and disruptive.
• Economic conditions could adversely affect customer demand and ability to pay.
• Currency exchange rate fluctuations could impact results of operations.
• The company may need additional financing in the future, which may not be available on favorable terms.
• Ongoing regional conflicts could have a material adverse effect on the business and results of operations.

Future Outlook

Avanos expects its operating cash flow will be sufficient to meet working capital requirements and fund capital expenditures in the next twelve months and expects the Transformation Process will be substantially complete by the end of 2025.

Management Comments

• Management is focused on delivering clinically superior medical device solutions.
• Management is committed to addressing important healthcare needs, including nutrition and pain management.
• Management plans to pursue efficient capital allocation strategies, including acquisitions.

Industry Context

Avanos operates in a competitive medical device industry, facing competition from various companies and alternative clinical practices. The company's ability to compete is impacted by technological advances, pricing pressures, and reimbursement practices. The company is focused on innovation and portfolio optimization to maintain its market position.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or benchmarks.
• However, it mentions competitors such as Boston Scientific Corporation, Pacira Pharmaceuticals, Inc., Stryker Corporation, and Medtronic plc.
• A detailed comparison would require analyzing these competitors' financial results and market positions.

Management Changes

Legal Proceedings

• The company is subject to various legal proceedings, claims, and governmental inspections.
• A Deferred Prosecution Agreement (DPA) with the DOJ related to MicroCool surgical gowns expired on July 7, 2024, and the case was dismissed in January 2025.

Stakeholder Impact

• Shareholders are impacted by the net loss and impairment charges, leading to a decrease in stock price performance.
• Employees may be affected by restructuring activities and organizational changes.
• Customers and healthcare providers can expect continued focus on Digestive Health and Pain Management and Recovery products.
• Suppliers may be impacted by changes in the supply chain and manufacturing operations.

Next Steps

• The company will continue to execute its three-year transformation process.
• Avanos will focus on Digestive Health and Pain Management and Recovery product categories.
• The company will pursue efficient capital allocation strategies, including acquisitions.
• Avanos will monitor and manage risks related to competition, supply chain, and regulatory compliance.

Key Dates